Is Cerus Corporation (CERS) a Buy, Sell, or Hold?
NASDAQ : CERS
Cerus Corporation
$2.32 USD
$0.05 (2.2%)
- Volume
- 2.39M
- Average Volume
- 2.76M
- Market Capitalization
- $467.54M
- P/E Ratio
- -64.09
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $3.47
- Year Low
- $1.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.83
Company Overview
NASDAQ
Vivek K. Jayaraman
Medical - Devices
Healthcare
CERS
275
US
USD
Liquidity Metrics
1.10
1.83
1.07
0.21
0.00
Sales & Valuation
$206.13M
2.11
6.65
-255.62
-0.01
Profitability
-$0.082
-$15.63M
-3.06%
-2.91%
-10.31%
-3.31%
P/E Metrics
-64.09
-0.58
-0.58
Analyst Price Target & Rating
$4.00
$4.00
$4.00
2/5
10 Analysts
-42.00%
Financial Health Scores
-3.92
4/9
$71.52M
$205.19M
$134.47M
$1.22M
Key Metrics (TTM)
$516.28M
2.33
177.54
1.83
-10.31%
-1.06%
-1.49%
-0.40%
162 days
Company Executives
| Name | Title |
|---|---|
| Laurence Corash | Co-Founder & Chief Scientific Officer |
| Kevin D. Green | Vice President of Finance & Chief Financial Officer |
| Vivek K. Jayaraman | President, Chief Executive Officer & Director |
| William Greenman | Executive Chairman of the Board |
| Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary |
| Richard J. Benjamin | Chief Medical Officer |
| Carol Moore | Senior Vice President of Regulatory Affairs, Quality & Clinical |
| Timothy J. Lee | Head of Investor Relation |
| Nina Mufti | Senior Vice President of Research & Development |
| Lainie Corten | Vice President of Global Marketing |
Poll Results
No votes yet today — be the first to share your view!
About Cerus Corporation (NASDAQ:CERS) Stock
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, part ... icularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
2026-07-30 23:33:14
Cerus Corporation (CERS) Q2 2026 Earnings Call Transcript
Cerus Q2 Earnings Call Highlights
2026-07-30 18:06:34
Cerus NASDAQ: CERS reported second-quarter product revenue growth of 10% year over year and raised the low end of its 2026 product revenue outlook, citing demand for its INTERCEPT blood-safety products in North America and overseas.
Cerus Corporation Announces Second Quarter 2026 Financial Results
2026-07-30 16:01:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2026, and provided a business update. “This quarter we made significant progress in expanding patient access to safer blood components around the globe,” said Vivek Jayaraman, Cerus' president and chief executive officer. “I'm particularly pleased with the performance of our INTERCEPT Fibrinogen Complex (IFC) franchise in the U.S. The value proposition for b.
Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERS
2026-07-21 03:17:20
Amova Asset Management Americas Inc. reduced its stake in shares of Cerus Corporation (NASDAQ: CERS) by 4.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,516,606 shares of the biotechnology company's stock after selling 193,353 shares during
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
2026-07-16 16:01:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.
2026-06-17 08:30:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.
Cerus Corporation Closes New Debt Facility of Up to $110 Million
2026-06-08 08:30:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million reduction in outstanding term loan balance. Initial proceeds from the loan, togethe.
2026-05-27 11:35:00
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of the Company's negative returns and failure to achieve profitability over the past.
Frequently Asked Questions
-
What is the current Cerus Corporation (CERS) stock price?
-
Cerus Corporation(NASDAQ:CERS) stock price is $2.32 in the last trading session. During the trading session, CERS stock reached the peak price of $3.47 while $1.15 was the lowest point it dropped to. The percentage change in CERS stock occurred in the recent session was 2.2% while the dollar amount for the price change in CERS stock was $0.05.
-
CERS's industry and sector of operation?
-
The NASDAQ listed CERS is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of CERS?
-
Laurence Corash | Co-Founder & Chief Scientific Officer
Kevin D. Green | Vice President of Finance & Chief Financial Officer
Vivek K. Jayaraman | President, Chief Executive Officer & Director
William Greenman | Executive Chairman of the Board
Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary -
How many employees does CERS have?
-
Number of CERS employees currently stands at 275. CERS operates from 1220 Concord Avenue, Concord, CA 94520, US.
-
Link for CERS official website?
-
Official Website of CERS is: https://www.cerus.com
-
How do I contact CERS?
-
CERS could be contacted at phone #925 288 6000 and can also be accessed through its website. CERS operates from 1220 Concord Avenue, Concord, CA 94520, US.
-
How many shares of CERS are traded daily?
-
The average number of CERS shares traded daily for last 3 months was 2.76M.
-
What is the market cap of CERS currently?
-
The market value of CERS currently stands at $467.54M with its latest stock price at $2.32